$-0.05
(Market cap
$349 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
3.1
P/B Ratio
3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.6
-
Face value
--
-
Shares outstanding
174,270,558
10 Years Aggregate
CFO
$-118.65 Mln
EBITDA
$-169.83 Mln
Net Profit
$-156.51 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Palisade Bio (PALI)
| -17.0 | -0.5 | -8.0 | 188.5 | 39.6 | -57.2 | -60.9 |
|
BSE Sensex
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Palisade Bio (PALI)
| 42.4 | 177.3 | -88.7 | -92.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Palisade Bio (PALI)
|
2.0 | 348.5 | 0.5 | -31.9 | -2,609.0 | -25.4 | 3.1 | 3.0 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 263.0 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Palisade Bio (PALI)
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate... includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado. Read more
-
CEO, CFO & Director
Mr. J. D. Finley
-
CEO, CFO & Director
Mr. J. D. Finley
-
Headquarters
Denver, CO
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Palisade Bio (PALI)
What is the current share price of Palisade Bio Inc (PALI) Today?
The share price of Palisade Bio Inc (PALI) is $1.95 (NASDAQ) as of 31-Aug-2026 16:20 EDT. Palisade Bio Inc (PALI) has given a return of 39.65% in the last 3 years.
What is the current PB & PE ratio of Palisade Bio Inc (PALI)?
The P/E ratio of Palisade Bio Inc (PALI) is 3.08 times as on 28-Aug-2026.
The P/B ratio of Palisade Bio Inc (PALI) is 3.01 times as on 28-Aug-2026, a 42 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-7.80 |
1.01 |
2024 |
-0.98 |
1.88 |
2023 |
-0.44 |
0.48 |
2022 |
-0.66 |
0.75 |
2021 |
-0.01 |
0.05 |
What is the 52 Week High and Low of Palisade Bio Inc (PALI)?
The 52-week high and low of Palisade Bio Inc (PALI) are Rs 2.86 and Rs 0.53 as of 01-Sep-2026.
What is the market cap of Palisade Bio Inc (PALI)?
Palisade Bio Inc (PALI) has a market capitalisation of $ 349 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Palisade Bio Inc (PALI)?
Before investing in Palisade Bio Inc (PALI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.